AMPH vs LLY: fair value comparison
Amphastar Pharmaceuticals, Inc. and Eli Lilly and Company · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LLY currently sits closer to the top of our discount ranking. AMPH carries the stronger quality grade. AMPH carries the stronger momentum grade.
| AMPH | LLY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $20.22 | $1,174.61 |
| 12-month range | $18.42–$30.81 | $735.19–$1,148.84 |
| Sector rank | #15 of 113 Healthcare | #12 of 113 Healthcare |
| Quality grade | C- | D |
| Momentum grade | A | B |
| Leverage | Moderate | High |
| Margin trend | — | Expanding |
| Revenue growth | — | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: AMPH fair value analysis · LLY fair value analysis